Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Identification of Novel Therapeutic Targets in Atm-Deficient Lymphomas Using a Whole Genome CRISPR/CAS-9 Screen

Tatjana Stankovic, MD PhD, Nicholas Davies, PhD, Louise J Tee, Andrew D Beggs, Malcolm Taylor, PhD

Blood (2019) 134 (Supplement_1): 1504.

https://doi.org/10.1182/blood-2019-129974

Published: 2019

Journal Articles

Targeting an RNaseH2 Defect in Chronic Lymphocytic Leukaemia with PARP Inhibitors

Angelo Agathaggelou, Olga Murina, Andrew P Jackson, Paul Moss, MBBS, PhD FRCP, Shankara Paneesha, MD, Grant S Stewart, Malcolm Taylor, PhD, Tatjana Stankovic, MD PhD

Blood (2018) 132 (Supplement 1): 1835.

https://doi.org/10.1182/blood-2018-99-115967

Published: 2018

Journal Articles

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3004.

https://doi.org/10.1182/blood.V130.Suppl_1.3004.3004

Published: 2017

Journal Articles

A Novel Role of PALB2 in Lymphoid Tumour Development

Tatjana Stankovic, MD PhD, Philip J Byrd, PhD, Grant S Stewart, PhD, Alexander J Taylor, Anna Smith, Peggy Fooks, Robert Horsley, James I Last, PhD, Dragana Janic, MD PhD, Lidija Dokmanovic, MD PhD, Antony W Oliver, PhD, A.Malcolm R Taylor, PhD

Blood (2016) 128 (22): 5113.

https://doi.org/10.1182/blood.V128.22.5113.5113

Published: 2016

Journal Articles

PALB2 Mutational Status in Haematopoeitic Malignancies - a Potential Therapeutic Target?

Ceri Oldreive, PhD BSc, Tatjana Stankovic, MD PhD, Philip J Byrd, PhD, Grant S Stewart, PhD, Anna Smith, Alexander J Taylor, Peggy Fooks, Robert Horsley, James I Last, Dragana Janic, MD PhD, Lidija Dokmanovic, MD PhD, A. Malcolm R Taylor

Blood (2016) 128 (22): 2726.

https://doi.org/10.1182/blood.V128.22.2726.2726

Published: 2016

Journal Articles

A New Murine Model for B Cell Malignancies on ATM-Deficient Background Reveals Involvement of Multiple Pathogenic Mechanisms

Tegan A Francis, PhD, Nicholas J Davies, PhD, Michael John Griffiths, BSc, Angelo Agathanggelou, PhD, Maha Ibrahim, Paul G. Murray, PhD, Zbigniew Rudzki, Tatjana Stankovic, MD PhD, Alexander M R Taylor, PhD

Blood (2016) 128 (22): 4093.

https://doi.org/10.1182/blood.V128.22.4093.4093

Published: 2016

Journal Articles

CLL Progression Is Associated with Increased Clonal Diversity and Replication Stress

Angelo Agathanggelou, PhD, Anna Skowronska, PhD, Nick Davies, PhD, Marwan Kwok, MB ChB, MRCP, Samuel Clockie, Mike Griffiths, Alexander Taylor, Tatjana Stankovic, MD PhD

Blood (2014) 124 (21): 1977.

https://doi.org/10.1182/blood.V124.21.1977.1977

Published: 2014

Journal Articles

Primary CLL Xenograft: A Model System to Study the Role of T-Cells in CLL Biology and Therapeutic Response

Ceri E Oldreive, PhD, Anna Skowronska, PhD, Angelo Agathanggelou, PhD, Helen M Parry, Sergey Krysov, Graham K Packham, PhD, Rudzki Zbgniew, Guy Pratt, A. Malcolm R Taylor, PhD, Paul Moss, MDPhD, Tatjana Stankovic, MD PhD

Blood (2014) 124 (21): 3284.

https://doi.org/10.1182/blood.V124.21.3284.3284

Published: 2014

Journal Articles

ATR Inhibition Exacerbates Replication Stress in TP53 or ATM Deficient CLL Cells and Enhances Sensitivity to Chemotherapy and Targeted Therapy

Marwan Kwok, MB ChB, MRCP, Nicholas Davies, PhD, Angelo Agathanggelou, PhD, Edward Smith, BSc, Eva Petermann, PhD, Eliot Yates, BMedSc, Jeffrey Brown, PhD, Alan Lau, PhD, Tatjana Stankovic, MD PhD

Blood (2014) 124 (21): 3340.

https://doi.org/10.1182/blood.V124.21.3340.3340

Published: 2014

Journal Articles

The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial

Doreen te Raa, MD, Arnon P. Kater, MD PhD, Wendim Ghidey Alemayehu, Alexander Jethwa, Jennifer Hullein, Eric Eldering, PhD, Tatjana Stankovic, MD, PhD, Thorsten Zenz, MD, Christian H Geisler, Marinus H.J. Van Oers, MD, PhD

Blood (2013) 122 (21): 2861.

https://doi.org/10.1182/blood.V122.21.2861.2861

Published: 2013

Journal Articles

Synthetic Lethality In CLL With DNA Damage Response Defect By Targeting ATR Pathway

Tatjana Stankovic, MD, PhD, Davies Nicholas, Marwan Kwok, Edward Smith, Eliot Yates, Angelo Agathanggelou, Brown Jeff, Alan Lau

Blood (2013) 122 (21): 120.

https://doi.org/10.1182/blood.V122.21.120.120

Published: 2013

Journal Articles

Targeted Treatments: Pre-Clinical Evaluation Of Efficacy By Tracking Clonal Diversity In CLL Xenograft Models

Nicholas J Davies, Ceri E Oldreive, PhD, Angelo Agathanggelou, Clive Gould, Guy Pratt, Mike Griffiths, Tatjana Stankovic, MD, PhD

Blood (2013) 122 (21): 875.

https://doi.org/10.1182/blood.V122.21.875.875

Published: 2013

Journal Articles

Primary CLL Xenograft: T-Cells Friend or Foe? the Role of T-Cells in the Primary CLL Xenograft Model.

Ceri Oldreive, Anna Skowronska, Paul Moss, Alexander Taylor, Tatjana Stankovic, MD, PhD

Blood (2012) 120 (21): 2888.

https://doi.org/10.1182/blood.V120.21.2888.2888

Published: 2012

Journal Articles

The Ataxia Telangiectasia Nude Mouse with No Risk of Thymoma: A Model to Investigate Tumour Development of B Cell and Myeloid Origin Associated with ATM Loss

Tatjana Stankovic, MD, PhD, Phil Byrd, Tegan Francis, Teresa Marafioti, Zbigniew Rudzki, Alexander MR Taylor

Blood (2012) 120 (21): 1320.

https://doi.org/10.1182/blood.V120.21.1320.1320

Published: 2012

Journal Articles

Inhibition of Histone Deacetylase Activity Compromises Homologous Recombination Repair and Increases Sensitivity of Chemo-Resistant Chronic Lymphocytic Leukemia Cells to Olaparib

Angelo Agathanggelou, David Cartwright, Helen Parry, Guy Pratt, Paul Moss, Tatjana Stankovic, MD, PhD

Blood (2012) 120 (21): 3891.

https://doi.org/10.1182/blood.V120.21.3891.3891

Published: 2012

Journal Articles

Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.

Doreen te Raa, MD, Jitka Malcikova, Dr, PhD, Marek Mraz, Sarka Pospisilova, PhD, Magali Le Garff-Tavernier, Helene Merle-Beral, MD, PhD, Tatjana Stankovic, MD., PhD, Marinus H. J. van Oers, MD PhD, Eric Eldering, PhD, Stephan Stilgenbauer, MD, Thorsten Zenz, MD, PhD, Arnon P. Kater, MD PhD

Blood (2012) 120 (21): 2872.

https://doi.org/10.1182/blood.V120.21.2872.2872

Published: 2012

Journal Articles

The Correlation Between Deletion Architecture, ATM Mutational Status and BIRC3 Disruption in 11q-Deleted CLL

Matthew JJ Rose-Zerilli, PhD, Jade Forster, Helen Parker, PhD, Anton Parker, Ana E Rodríguez, Tracy Chaplin, Anne Gardiner, Andrew Collins, PhD, Bryan D Young, PhD, Tatjana Stankovic, MD., PhD, David Oscier, MD, Jonathan C. Strefford, BSc, PhD

Blood (2012) 120 (21): 658.

https://doi.org/10.1182/blood.V120.21.658.658

Published: 2012

Journal Articles

SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy

Doreen te Raa, MD, Ingrid AM Derks, Dieuwertje M Luijks, Jacoline van Laar, Hanneke Monsuur, Ceri Oldreive, Alexander Jethwa, Jennifer Hüllein, Tatjana Stankovic, MD PhD, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD, PhD, Arnon P. Kater, MD PhD, Eric Eldering, PhD

Blood (2012) 120 (21): 711.

https://doi.org/10.1182/blood.V120.21.711.711

Published: 2012

Journal Articles

Tyrosine Kinase Inhibitor Screen Identifies the Multikinase Inhibitor, Foretinib, As a Sensitisor of Treatment-resistant B-Precursor ALL to Core Chemotherapeutic Agents

Shaun R Wilson, MBChB, MRCPCH, Victoria J Weston, PhD, Tatjana Stankovic, MD, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD

Blood (2011) 118 (21): 1509.

https://doi.org/10.1182/blood.V118.21.1509.1509

Published: 2011

Journal Articles

Inhibition of BRD4 Bromodomains Is a Potent Novel Strategy to Target Apoptosis Resistance in Paediatric ALL

David Da Costa, Victoria J Weston, PhD, Wenbin Wei, PhD, Angelo Agathanggelou, PhD, Eva Petermann, PhD, Stefan Knapp, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD, Tatjana Stankovic, MD, PhD

Blood (2011) 118 (21): 77.

https://doi.org/10.1182/blood.V118.21.77.77

Published: 2011

NARROW

Identification of Novel Therapeutic Targets in Atm-Deficient Lymphomas Using a Whole Genome CRISPR/CAS-9 Screen

Targeting an RNaseH2 Defect in Chronic Lymphocytic Leukaemia with PARP Inhibitors

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

A Novel Role of PALB2 in Lymphoid Tumour Development

PALB2 Mutational Status in Haematopoeitic Malignancies - a Potential Therapeutic Target?

A New Murine Model for B Cell Malignancies on ATM-Deficient Background Reveals Involvement of Multiple Pathogenic Mechanisms

CLL Progression Is Associated with Increased Clonal Diversity and Replication Stress

Primary CLL Xenograft: A Model System to Study the Role of T-Cells in CLL Biology and Therapeutic Response

ATR Inhibition Exacerbates Replication Stress in TP53 or ATM Deficient CLL Cells and Enhances Sensitivity to Chemotherapy and Targeted Therapy

The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial

Synthetic Lethality In CLL With DNA Damage Response Defect By Targeting ATR Pathway

Targeted Treatments: Pre-Clinical Evaluation Of Efficacy By Tracking Clonal Diversity In CLL Xenograft Models

Primary CLL Xenograft: T-Cells Friend or Foe? the Role of T-Cells in the Primary CLL Xenograft Model.

The Ataxia Telangiectasia Nude Mouse with No Risk of Thymoma: A Model to Investigate Tumour Development of B Cell and Myeloid Origin Associated with ATM Loss

Inhibition of Histone Deacetylase Activity Compromises Homologous Recombination Repair and Increases Sensitivity of Chemo-Resistant Chronic Lymphocytic Leukemia Cells to Olaparib

Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.

The Correlation Between Deletion Architecture, ATM Mutational Status and BIRC3 Disruption in 11q-Deleted CLL

SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy

Tyrosine Kinase Inhibitor Screen Identifies the Multikinase Inhibitor, Foretinib, As a Sensitisor of Treatment-resistant B-Precursor ALL to Core Chemotherapeutic Agents

Inhibition of BRD4 Bromodomains Is a Potent Novel Strategy to Target Apoptosis Resistance in Paediatric ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only